A novel HSP90 modulator with selective activity against thyroid cancers in vitro

被引:40
作者
Samadi, Abbas
Loo, Peter
Mukerji, Rithwi
O'Donnell, Gemma [2 ]
Tong, Xiaqin [2 ]
Timmermann, Barbara N. [2 ]
Cohen, Mark S. [1 ]
机构
[1] Univ Kansas, Dept Surg, Med Ctr, Sutherland Inst 2035, Kansas City, KS 66160 USA
[2] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA
关键词
INHIBITORS; HEAT-SHOCK-PROTEIN-90; CARCINOMA; CHAPERONE; MUTATION; ANALOGS;
D O I
10.1016/j.surg.2009.09.028
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Heat shock protein 90 (HSP90) is a chaperone protein regulating several client proteins involved in thyroid cancer development. The Purpose of this study was to mechanistically evaluate a novel, natural product drug with anticancer activity in thyroid cancer cell lines in vitro for future translational applications. Methods. A total of 285 natural plant extracts and compounds were evaluated for anticancer activity by MTS assay. Apoptosis and cell cycle arrest were characterized by annexin V-propidium iodide (PI) flow cytometry. HSP90 and client protein modulation, as well as apoptosis confirmation, as demonstrated by Western, blot analysis. Results. Of the 285 compounds and products tested, 45 demonstrated antiproliferative activity in thyroid cancers by MTS assay. BTIMNP_D004 demonstrated the greatest inhibition (IC50 = 155-2,890 nM in thyroid cancers). Activity was cancer-cell selective compared to fibroblasts, with increased potency over 17-AAG in BCPAP, FTC133, and DRO81-1 cells. D004 modulated cell cycle arrest after 18 hours (G(1)/G(0)(->)S and G(2)/M) with 30% FTC133 cells shifted, 22% BCPAP cells shifted, and 15% SW1736 cells shifted versus controls (P < .01, P < .01, and P < .05, respectively). A total of 1 mu M D004 induced significant apoptosis, with 76% BCPAP cells gated after 18 hours (annexin V-PI staining vs <3% in controls, P < .01; and 80% FTC133 cells vs 4% controls; P < .01). Western blot analysis demonstrated modulation of HSP90 expression levels, with inhibition of HSF-1, AKT, and caspase-3 expression, and cleavage of PARP in both BCPAP and FTC133 cells. Conclusion. BTIMNP_D004 is a novel natural product drug with anticancer activity against thyroid cancers in vitro, and may act through induction of apoptosis, modulation of cell cycle arrest, and modulation of heat shock chaperone proteins including HSP90. These preliminary in vitro data support future preclinical studies for translational applications. (Surgery 2009;146:1196-207.)
引用
收藏
页码:1196 / 1207
页数:12
相关论文
共 25 条
[1]  
*AM CANC SOC, 2008, CANC FACTS FIG 2008, P5
[2]   The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future [J].
Banerji, Udai ;
Judson, Ian ;
Workman, Paul .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :385-390
[3]   Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation [J].
Blagg, BSJ ;
Kerr, TA .
MEDICINAL RESEARCH REVIEWS, 2006, 26 (03) :310-338
[4]   Hsp90 as a target for drug development [J].
Chaudhury, Subhabrata ;
Welch, Timothy R. ;
Blagg, Brian S. J. .
CHEMMEDCHEM, 2006, 1 (12) :1331-+
[5]  
Chiosis G, 2003, MOL CANCER THER, V2, P123
[6]   Mutation of the PIK3CA gene in anaplastic thyroid cancer [J].
García-Rostán, G ;
Costa, AM ;
Pereira-Castro, I ;
Salvatore, G ;
Hernandez, R ;
Hermsem, MJA ;
Herrero, A ;
Fusco, A ;
Cameselle-Teijeiro, J ;
Santoro, M .
CANCER RESEARCH, 2005, 65 (22) :10199-10207
[7]   Significance of BRAF mutations in papillary thyroid carcinoma:: prognostic and therapeutic implications [J].
Groussin, L ;
Fagin, JA .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (04) :180-181
[8]   Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer [J].
Hou, Peng ;
Liu, Dingxie ;
Shan, Yuan ;
Hu, Shuiying ;
Studeman, Kimberley ;
Condouris, Stephen ;
Wang, Yangang ;
Trink, Ariel ;
El-Naggar, Adel K. ;
Tallini, Giovanni ;
Vasko, Vasily ;
Xing, Mingzhao .
CLINICAL CANCER RESEARCH, 2007, 13 (04) :1161-1170
[9]   Pathogenetic mechanisms in thyroid follicular-cell neoplasia [J].
Kondo, T ;
Ezzat, S ;
Asa, SL .
NATURE REVIEWS CANCER, 2006, 6 (04) :292-306
[10]   Recent Advances in Hsp90 Inhibitors as Antitumor Agents [J].
Messaoudi, S. ;
Peyrat, J. F. ;
Brion, J. D. ;
Alami, M. .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (07) :761-782